John Fesko Sells 291 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 291 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $206.16, for a total transaction of $59,992.56. Following the completion of the sale, the insider directly owned 187,220 shares in the company, valued at $38,597,275.20. This represents a 0.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The stock was sold at an average price of $204.10, for a total transaction of $344,520.80.
• On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $144,319.91.

Natera Price Performance

NASDAQ:NTRA opened at $215.09 on Thursday. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36. The firm’s 50-day moving average price is $202.02 and its 200-day moving average price is $214.75. The company has a market capitalization of $30.61 billion, a PE ratio of -140.58 and a beta of 1.57.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same period in the prior year, the firm posted ($0.41) EPS. Equities analysts anticipate that Natera, Inc. will post -1.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Several institutional investors have recently made changes to their positions in the business. Horizon Investments LLC lifted its stake in shares of Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares during the period. Savvy Advisors Inc. lifted its stake in shares of Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares during the period. First Horizon Corp lifted its stake in shares of Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares during the period. Finally, Siemens Fonds Invest GmbH lifted its stake in shares of Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares during the period. Institutional investors own 99.90% of the company’s stock.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly results beat expectations: Natera reported $0.35 EPS and $665.5M revenue, well above consensus — this outperformance supports upside in the stock. Earnings and company page
• Positive Sentiment: Analyst support is generally constructive: several firms have recent Buy/Outperform notes and the consensus target (~$253.47) sits above current levels, which can attract momentum buyers. Analyst coverage
• Positive Sentiment: Institutional inflows noted (new/expanded stakes by firms such as Robinhood Asset Management and JPMorgan), indicating larger investors remain interested in the growth story. Institutional holdings
• Neutral Sentiment: Multiple insiders (CEO Steven Chapman, CFO Michael Brophy, John Fesko, Solomon Moshkevich) sold shares in early May under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vesting awards; these are scheduled, limited reductions rather than opportunistic dumps. Insider trades summary
• Negative Sentiment: Fundamentals still show profitability headwinds: Natera reports a negative net margin and negative ROE, and analysts model a negative EPS for the fiscal year, which leaves valuation and path‑to‑sustained profitability as open risks. Financial metrics and estimates

Wall Street Analyst Weigh In

Several brokerages recently commented on NTRA. Wall Street Zen raised shares of Natera from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a research report on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Citigroup began coverage on shares of Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective on the stock. Finally, Wells Fargo & Company increased their price objective on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.